Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer
Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer
Recruiting · NCT07635342 · Registry updated 2026-06-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | HER2-positive Breast Cancer | Recruiting | Phase 2 | 2026-06-09 | NCT07635342 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hebei Medical University Fourth Hospital | 83 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| the Fourth Hospital of Hebei Medical University | Shijiazhuang | China | 19 |